Eloxx Pharmaceuticals, Inc. — 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018; comparisons are primarily with 2017. This is an annual report, not a quarterly filing. Eloxx is a clinical-stage biopharmaceutical company with no approved products and no product revenue. Its lead candidate, ELX-02, is being developed for nonsense-mutation forms of cystic fibrosis and cystinosis.
Financial results and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $20.5 million | $16.4 million |
| General and administrative expense | $26.5 million | $2.7 million |
| Total operating expenses / operating loss | $47.6 million | $20.4 million |
| Net loss | $47.2 million | $21.2 million |
| Basic and diluted net loss per share | $1.45 | $4.75 |
| Net cash used in operating activities | $31.4 million | $15.9 million |
| Cash and cash equivalents at year-end | $48.6 million | $24.0 million |
At December 31, 2018, total assets were $50.7 million, current liabilities were $7.8 million, and stockholders’ equity was $42.9 million. The filing reports no revenue, so operating margins are not meaningful. No debt is shown on the year-end balance sheet; the prior convertible loan had converted to preferred stock in 2017.
Changes versus 2017 and unusual items
- Net loss more than doubled, while operating cash use rose to $31.4 million from $15.9 million.
- G&A increased by $23.8 million, principally reflecting $11.6 million of stock-based compensation, higher personnel costs, and $7.8 million in infrastructure-related legal, accounting, and other professional fees. Total stock-based compensation was $13.4 million, versus $0.1 million in 2017.
- R&D increased by $4.1 million, mainly from personnel costs and clinical-development subcontractor and consultant fees.
- 2017 included a $3.4 million R&D charge related to the Technion exit-fee claim; the claim was settled in 2018 through issuance of 569,395 shares.
- April 2018’s public offering raised approximately $53.6 million net. The company also received $2.2 million net from at-the-market share sales in 2018.
Outlook, risks, and contingencies
- Management expected year-end cash plus $14.8 million net proceeds from a January 2019 loan to fund current and planned operations into the second quarter of 2020. The company expects continuing losses and cash use and may need additional financing.
- In January 2019, the company borrowed $15 million under a secured loan agreement providing for up to $25 million in total advances. A further $10 million advance is conditional on clinical milestones and at least $75 million of additional equity proceeds. The loan carries a floating rate of at least 5.25%; principal amortization was scheduled to begin in February 2020, potentially deferred to February 2021 if conditions are met, with maturity in January 2023.
- Management expected to complete the Phase 1b multiple-ascending-dose study in the first half of 2019 and report top-line Phase 2 results in cystic fibrosis in the second half of 2019. The planned CF Phase 2 study would enroll up to 24 patients; the cystinosis study up to six. These are forward-looking expectations, not reported outcomes.
- Key risks include clinical and regulatory uncertainty, limited rare-disease patient enrollment, potential safety issues, reliance on third-party manufacturers and research organizations, and the need for additional capital. The filing notes renal toxicity in preclinical animals at doses above those intended for clinical trials; in the single-dose healthy-volunteer study, treatment was generally well tolerated, with one moderate auditory event of unclear significance.
- The company depends on licensed technology from TRDF and has contingent royalty obligations to the Israeli Innovation Authority. It reported no material pending legal proceedings and no material off-balance-sheet arrangements.
- The independent auditor issued an unqualified opinion on the 2018 financial statements and internal controls; management also concluded disclosure controls and internal control over financial reporting were effective.
Investor verification priorities
- Confirm subsequent clinical-trial progress and results against the 2019 timelines stated in the filing.
- Review cash burn and financing needs against the stated runway, including the terms, collateral, covenants, and conditions of the January 2019 loan.
- Assess how much of the increased 2018 G&A reflects recurring costs versus stock-based compensation and public-company infrastructure.
- Verify clinical safety findings, particularly renal and auditory risks, as dose and duration increase.
- Monitor whether patent, licensing, IIA royalty, and contingent technology-transfer obligations could affect future economics or operations.